Randomized, Double-Blind, Placebo-Controlled Study of Anti-Mycobacterial Therapy (RHB-104) in Active Crohn’s Disease

This study, conducted between 4 October 2013, and 30 November 2018, tested the hypothesis that triple antimicrobial therapy, targeting <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> (MAP), long considered a putative cause, would favorably affect Crohn’s disease...

全面介绍

书目详细资料

发表在:	Antibiotics
Main Authors:	David Y. Graham, Saleh A. Naser, Thomas Borody, Zbigniew Hebzda, Harry Sarles, Scott Levenson, Robert Hardi, Tomasz Arłukowicz, Petar Svorcan, Reza Fathi, Aida Bibliowicz, Patricia Anderson, Patrick McLean, Clara Fehrmann, M. Scott Harris, Shuhong Zhao, Ira N. Kalfus
格式:	文件
语言:	英语
出版:	MDPI AG 2024-07-01
主题:	RHB-104 Crohn’s disease <i>Mycobacterium avium</i> subspecies <i>paratuberculosis</i> clinical trial clarithromycin rifabutin
在线阅读:	https://www.mdpi.com/2079-6382/13/8/694